Inflection risk review for late-stage biotech

Most inflection failures are predictable. Few are predicted.

The risks that derail a Phase 2/3 readout, PDUFA date or launch usually sit between functions, in questions each team reasonably expects another to own. Inflection Strategy asks those questions 6–18 months ahead, drawing on what approval and reimbursement actually require, while there is still time to act.

Start a conversation See an example

Not ready to talk? Read At the Inflection — free case studies on biotech execution risk.

27domains
Nearly 400diagnostic questions
110documented failure patterns

Each review applies only the questions that matter for your company and your inflection.

The core conviction

The science is only half the risk.

Three of every four FDA rejection letters published for 2020–2024 involved quality or manufacturing issues.

Efficacy decides many outcomes. But about one in five late-stage failures is commercial or strategic, and many efficacy failures trace back to choices made long before the readout: how the trial was powered, which endpoint was chosen, whether payers were ever asked. Those are execution decisions, and they leave signals early.

The framework is most valuable 6–18 months before the inflection event. The gap that looks manageable at 18 months becomes a crisis at 6.

Sources: Pharma Manufacturing analysis of FDA complete response letters (150 of 202); Hwang et al., JAMA Internal Medicine (22% of late-stage failures commercial or strategic).

Why it goes unseen

The risk sits where functions meet.

Most biopharma organizations are built for functional excellence. Clinical, regulatory, manufacturing and commercial each have clear goals, strong leaders and rigorous reviews. What that structure doesn't naturally produce is ownership of the questions that sit between functions. Will the endpoint strategy support what payers need? Will manufacturing be ready on the date the submission assumes? How will decisions be made once the data arrives? These questions don't go unanswered because of anyone's oversight. They go unanswered because the organization was never designed to assign them to anyone.

That's how failures cascade. An open question becomes a delay, the delay becomes a weaker submission or launch, and by the time the problem shows up, it has already spread to areas that looked fine. At an inflection point, even a few months can affect market position, investor confidence and the value of the asset.

The Inflection Strategy Framework is built to ask those questions early. It starts with an initial assessment that shows where to look more closely, so the work stays focused on what matters most.

What the diagnostic surfaces

The patterns that repeat.

Six of the 110 failure patterns in the Inflection Strategy Framework, each documented with its root cause, earliest detection point and the cases where it has appeared.

The PAI Surprise

No mock pre-approval inspection. Manufacturing and regulatory operate independently. The result is a CRL driven by manufacturing observations and a 6–18 month delay.

Earliest detection18–24 months before PDUFA

The Surrogate Endpoint Disconnect

A surrogate endpoint is chosen for speed without payer validation. Approval comes, access is restricted, and revenue is delayed two to three years.

Earliest detectionPhase 2/3 design, before endpoint lock

The Phase 2b Extrapolation Trap

Phase 3 is powered on the Phase 2 point estimate rather than the lower bound of the confidence interval: a design built for the best plausible outcome, not a realistic one. Phase 3 fails despite the Phase 2 signal, and the choice becomes termination or a redesigned trial that adds two to three years.

Earliest detectionPhase 3 design, before initiation

The Clinical–Commercial Interface Vacuum

A first-time commercial build runs alongside the clinical organization with no named integration owner and no documented decision rights at the boundary. Questions default to the CEO, and in the first 90 days of launch, decisions that should take hours take weeks.

Earliest detectionThe moment commercial hiring begins

The Board Surprise

Board materials present only the optimistic case. When results disappoint, the board steps in and management authority is constrained.

Earliest detection18–24 months before the inflection

The Alignment Illusion

The CEO, CMO and CCO use different language when interviewed separately. Group discussions produce agreement without debate, and the consensus fractures under pressure.

Earliest detectionBefore the engagement, in separate C-suite interviews

What the output looks like

An illustrative diagnostic signal.

A composite example of a late-stage biotech approaching commercialization, with positive clinical momentum.

Illustrative example · late-stage biotech · pre-launchElevated risk

Signals observed

  • Commercial readiness lagged milestone timing; launch-critical capabilities weren't aligned to the expected inflection.
  • A leadership transition blurred decision ownership, escalation, and execution speed.
  • Handoffs between regulatory, medical, market access, and commercial showed emerging strain as complexity grew.
  • Planning was milestone-aware, but not milestone-anchored.

Interpretation

No single finding signaled failure. The risk came from the interaction — leadership transition, readiness gaps, and cross-functional pressure compounding ahead of a critical event.

Earliest detection

Detectable 12–18 months before launch, when commercial hiring began without a named integration owner.

Recommended next step

Milestone-anchored risk reviews, clarified executive decision governance, and commercial capabilities sequenced 12–18 months ahead of the inflection — each fix with a named owner.

At the Inflection · recent analyses

The framework, applied to real companies.

Public case studies of biotech execution failures — and what they reveal about organizational risk at the inflection point.

Gilead · ImmunomedicsThe Sunk Cost Spiral ReplimuneThe FDA Told Them. Twice. BioMarinThe Data Was Screaming. Management Turned Up the Volume on Their Own Conviction. Ocular TherapeutixYou Won the Trial. Why Did the Stock Drop 25%?

Subscribe to At the Inflection →

How it works

A structured diagnostic, not a template.

1

Define the inflection

Pin down the moment you're approaching — Phase 2/3 readout, PDUFA, launch, or scale-up. Each carries a different risk profile.

2

Ask and test

An initial assessment identifies where risk is most likely to build, and the deeper questions are focused there. Structured interviews at three levels — CEO and board, C-suite, VP — are captured live in a purpose-built session instrument. Each answer is tested against a defined red-flag threshold, and each domain is rated Elevated, Watch, or Clear.

3

Report and act

A written report for the CEO and board: where risk sits, which handoffs are fragile, and what to fix first. Each gap comes with a named owner and a specific fix.

Before the inflection

Inflection Risk Review

For companies 6–18 months from a Phase 2/3 readout, PDUFA date, or launch. A structured assessment of where execution risk sits, which handoffs are fragile, and what to fix first, while there is still time to fix it.

After a setback

Setback Review

For companies recovering from a Complete Response Letter, a missed endpoint, a delayed launch, or a restructuring. What broke, why, and which gaps still put the next milestone at risk.

Both engagements include

  • Completed within three weeks of kickoff
  • 6–12 confidential leadership interviews
  • Written review with ranked gaps, each paired with a specific fix
  • Readout with the CEO; optional session with the leadership team or board

What the framework covers

27 diagnostic domains and nearly 400 questions, organized in four areas. Each review draws only on the domains that matter for your company and your inflection.

Regulatory, clinical & operations

FDA strategy, medical affairs, biostatistics, manufacturing, pharmacovigilance, clinical data, AI and digital infrastructure.

Commercial & access

Launch readiness and sequencing, market access, commercial operations, patient and physician adoption, post-approval scale-up.

Capital & strategy

Investor relations, capital markets, M&A and business development, portfolio allocation, loss of exclusivity, geopolitical risk.

Leadership & organization

Executive alignment, decision governance, narrative discipline, leadership depth, organizational transition.

Read the full framework explainer →

About

Larry Chaityn, Principal

Larry Chaityn, Principal, Inflection Strategy

My work sits at the intersection of strategy, talent, and commercial execution in life sciences: business development at Capgemini, life sciences consulting at Oracle, senior executive search, and founding an angel network's life sciences chapter.

"The same gap that looked manageable at 18 months out becomes a crisis at 6 months."

Across dozens of organizations at their most pressured moments, I saw the same execution failures repeat. They are not random. They leave signals early. The Inflection Strategy Framework is the structure I built to find them.

Every question traces to industry best practice or a documented failure. Each failure pattern records its root cause and earliest detection point, and the case library is checked for accuracy through external review.

This is not turnaround consulting. It is work for organizations that are fundamentally sound — before an inflection, or right after a setback — and need an outside view of their blind spots. When a review reveals a leadership gap, my search firm, Life Science Recruiters of North America, helps define the role and find the right leader.

  • Business Development Lead, Capgemini; Life Sciences Consulting, Oracle Life Sciences
  • Founder, Life Science Recruiters of North America; executive search at The Steely Group and Adecco Medical
  • Founder & Life Sciences Chapter Lead, Keiretsu Forum NY/Tri-State — presented 112 life sciences companies to angel investors
  • Author, At the Inflection on Substack

Connect

Approaching a critical inflection? Let's talk.

Start with a 30-minute inflection risk conversation, at no cost. Tell me where you are relative to your inflection, and I'll tell you where I'd look first. I respond to every inquiry personally.

Email
larry@inflectionstrategy.co
Location
New York, NY
LinkedIn
Larry Chaityn

Message received. Larry will be in touch shortly.